Profiles

Andrew Palmer

UTAS Home Professor Andrew Palmer

Andrew Palmer

New Star Professor of Medical Research, Founding Chair, Health Economics Research Unit
Menzies Institute for Medical Research

Room 353b-02 (Level 3), Medical Science 2, Hobart CBD Campuses

+61 3 6226 7729 (phone)

Andrew.Palmer@utas.edu.au

Prof Andrew Palmer is a New Star Professor of Medical Research and the Head of the Health Economics Research Unit at Menzies, working in the field of health economics since 1994. He is a leader in the subject of health economics in chronic diseases, has conducted research and published extensively in many disease areas including aged care/dementia, diabetes, multiple sclerosis, kidney disease, hypertension, dyslipidaemia, osteoporosis, alcoholism, growth hormone deficiency, rheumatoid arthritis, cardiovascular disease and oncology.

As well as being the Associate Editor (Health Economics) of Diabetic Medicine, he is the 2013-15 International Diabetes Federation (IDF) Chairman of the Task Force on Health Economics, the Co-founder/current Steering Committee member of the Mount Hood Modelling Diabetes Group, a Member of the 2013-15 Heart Foundation Future Fellows Selection Committee, member of the 2013-15 National Diabetes Strategy Group reporting to the Federal Minister for Health, Member of the Diabetes Australia Health Economics Expert Reference Group, and was an American Diabetes Association panel member for the development of diabetes health economics modelling guidelines.

Career summary

Qualifications

  • BmedSci, University of Tasmania, Australia, 1984
  • MBBS, University of Tasmania, Australia, 1987

Languages (other than English)

  • German (fluent written and oral)

Biography

Prof Palmer studied medicine at the University of Tasmania, after which he worked at the Launceston General Hospital, then as a general practitioner in Sydney. In 1994 he moved to Switzerland, where he was researcher and Medical Director of the Institute for Medical Informatics and Biostatistics (IMIB) from 1994 until 2000. CI Palmer co-founded CORE, Center for Outcomes Research, in Basel, Switzerland in July 2000 and was Medical Director and CEO until 2005. He was named by the International Society for Pharmacoeconomics and Outcomes Research as one of the top 10 most influential people in health economics in 2005.

Research Themes

Professor Palmer's research aligns with the university's research theme of Better Health. He has conducted research and published extensively in the area of health economics and the modelling of diabetes and diabetes prevention.

In addition to his work in the area of diabetes, CI Palmer has conducted research and published extensively in other disease areas including multiple sclerosis, nephropathy and renal failure, hypertension, dyslipidaemia, deep vein thrombosis and pulmonary embolism prevention, osteoporosis, alcoholism, growth hormone deficiency, rheumatoid arthritis, cardiovascular disease and oncology.

CI Palmer led the development of the CORE Diabetes Model, which has been used to inform reimbursement and policy decisions regarding diabetes interventions on an international scale. The CORE Diabetes Model is the most widely published diabetes health economics model, and has been used in over 30 reimbursement submissions for pharmaceutical agents and devices worldwide. The methodology applied by CI Palmer's team has been used as the basis for international recommendations for guidelines in diabetes modelling.

CI Palmer co-founded, has chaired and been an active member of the Steering Committee of the Mount Hood Modelling Group, committed to the increased accuracy, validity and usefulness of complex diabetes models throughout the world. He was part of the American Diabetes Association Panel for developing guidelines/recommendations on the development of models of diabetes. The data generated from the MS prevalence and cost of illness study was used by Australia's leading MS advocacy group, MS Research Australia, to lobby the federal government for implementation of the Disability Insurance Scheme (in the meantime this has been passed with bipartisan support in the Federal Parliament).

Memberships

Professional practice

  • International Diabetes Federation (IDF) Chairman of the Task Force on Health Economics, 2013-15
  • National Diabetes Strategy Group reporting to the Federal Minister for Health, 2014-15

Committee associations

  • Heart Foundation Future Fellows Selection Committee, 2013-2015

Administrative expertise

  • Founding chair and head of the Department of Health Economics, Menzies Institute for Medical Research, University of Tasmania
  • Co-founder and current Steering Committee member of the Mount Hood Modelling Diabetes Group, the world's leading international diabetes health economics development and validation group

Teaching

Decision analysis, Modelling, Health economics, Diabetes, TreeAge software

Teaching expertise

  • Introduction to health economics
  • Practical methods in health economics
  • TreeAge Decision Analysis Software

Research Appointments

  • Member of the 2013, 2014, 2015 Heart Foundation Future Fellows Selection Committee
  • Member of the 2013-15 National Diabetes Strategy Group reporting to the Federal Minister for Health
  • Member of the Diabetes Australia Health Economics Expert Reference Group
  • Chairman, International Diabetes Federation, Task Force on Health Economics

View more on Professor Andrew Palmer in WARP

Expertise

  • Bicycle accident research
  • Horse racing industry health economics
  • Diabetes health economics
  • Workplace health promotion health economics
  • Haemochromatosis health economics
  • Multiple sclerosis health economics
  • Obesity health economics
  • Bariatric surgery health economics
  • Osteoporosis health economics
  • Aged care health economics

Awards

  • ISPOR Asia-Pacific 2014 Best Research Poster Presentation
  • International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia-Pacific 2010: Best Research Podium Presentation
  • ISPOR Asia-Pacific 2010: Best Research Podium Presentation
  • Named by International Society for Pharmacoeconomics and Outcomes Research (ISPOR) as 'one of the 10 most influential people in the field of health economics and outcomes research in 2005'
  • ISPOR Europe 2005: Best Contributed Podium Presentation (first author)
  • ISPOR Europe 2004: Best Contributed Podium Presentation (co-author)
  • Deutsche Medizinische Wochenschrift (German Medical Journal) Walter Siegenthaler Preis 2001 (DMW Journal Article of the Year, 2001)

Current projects

  1. Bariatric surgery in Tasmania: investigating health service use, costs, patient outcomes and policy options
  2. Development of new diabetes health outcomes model
  3. Development of new osteoporosis health outcomes model
  4. Diabetes - Cost effectiveness of the COACH program in Tasmania, in association with Diabetes Tasmania
  5. Diabetes - Mount Hood Challenge Conference Series
  6. Haemochromatosis in Australia: a Cost of Illness Study
  7. Health Economics of Haemochromatosis
  8. Multiple Sclerosis - Development of an Australian Gold Standard Health Economics Model in conjunction with MS Research Australia
  9. Tasmanian Cycling Habits Accident Risk and Costs

Research Fields

  • Health Economics (140208)
  • Epidemiology (111706)
  • Public Health and Health Services (111799)
  • Central Nervous System (110903)
  • Aged Health Care (111702)
  • Cardiology (incl. Cardiovascular Diseases) (110201)
  • Residential Client Care (111718)
  • Rheumatology and Arthritis (110322)
  • Health and Community Services (111708)
  • Primary Health Care (111717)
  • Complementary and Alternative Medicine (110499)
  • Clinical Sciences (110399)
  • Endocrinology (110306)
  • Nephrology and Urology (110312)
  • Cardiorespiratory Medicine and Haematology (110299)
  • Health Promotion (111712)
  • Neurology and Neuromuscular Diseases (110904)
  • Aged Care Nursing (111001)
  • Paediatrics (111403)
  • Surgery (110323)
  • Respiratory Diseases (110203)
  • Autonomic Nervous System (110901)
  • Health, Clinical and Counselling Psychology (170106)
  • Health Information Systems (incl. Surveillance) (111711)
  • Gastroenterology and Hepatology (110307)
  • Health Care Administration (111709)
  • Geriatrics and Gerontology (110308)
  • Medical and Health Sciences (119999)
  • Psychiatry (incl. Psychotherapy) (110319)
  • Haematology (110202)
  • Sports Medicine (110604)
  • Preventive Medicine (111716)
  • Environmental and Occupational Health and Safety (111705)
  • Sociology (160899)
  • Applied Sociology, Program Evaluation and Social Impact Assessment (160801)
  • Infectious Diseases (110309)
  • Nursing (111099)
  • Mental Health (111714)
  • Architectural Science and Technology (incl. Acoustics, Lighting, Structure and Ecologically Sustainable Design) (120104)
  • Rehabilitation and Therapy (excl. Physiotherapy) (110321)
  • Allergy (110701)
  • Emergency Medicine (110305)
  • Clinical Nursing: Primary (Preventative) (111002)
  • Medicine, Nursing and Health Curriculum and Pedagogy (130209)
  • Peripheral Nervous System (110905)
  • Health Policy (160508)
  • Aboriginal and Torres Strait Islander Health (111701)

Research Impact

  • Health Policy Economic Outcomes (920207)
  • Evaluation of Health Outcomes (920204)
  • Nervous System and Disorders (920111)
  • Injury Control (920409)
  • Diabetes (920104)
  • Blood Disorders (920101)
  • Health and Support Services (920299)
  • Health Policy Evaluation (920208)
  • Cardiovascular System and Diseases (920103)
  • Health Related to Ageing (920502)
  • Skeletal System and Disorders (incl. Arthritis) (920116)
  • Public Health (excl. Specific Population Health) (920499)
  • Health Education and Promotion (920205)
  • Preventive Medicine (920412)
  • Specific Population Health (excl. Indigenous Health) (920599)
  • Nursing (920210)
  • Behaviour and Health (920401)
  • Respiratory System and Diseases (incl. Asthma) (920115)
  • Mental Health (920410)
  • Urogenital System and Disorders (920119)
  • Health (929999)
  • Neurodegenerative Disorders Related to Ageing (920112)
  • Clinical Health (Organs, Diseases and Abnormal Conditions) (920199)
  • Allied Health Therapies (excl. Mental Health Services) (920201)
  • Health Status (e.g. Indicators of Well-Being) (920408)
  • Surgical Methods and Procedures (920118)
  • Disease Distribution and Transmission (incl. Surveillance and Response) (920404)
  • Digestive System Disorders (920105)
  • Substance Abuse (920414)
  • Carer Health (920202)
  • Infectious Diseases (920109)
  • Cancer and Related Disorders (920102)
  • Disability and Functional Capacity (920403)
  • Ageing and Older People (940103)
  • Education and Training Systems Policies and Development (930501)
  • Road Safety (880109)
  • Residential Construction Design (870204)
  • Fixed Line Telephone Networks and Services (890102)
  • Immune System and Allergy (920108)
  • Occupational Health (920505)
  • Rural Health (920506)
  • Palliative Care (920211)

Publications

Prof Palmer has an H-Index of 25 (Scopus January 31, 2014), over 100 PubMed-listed publications; 1,916 citations; article with highest number of citations=174; 19 articles cited more than 30 times.

He has been a reviewer for a number of major international journals and societies, including American Journal of Kidney Disease, Annals of Internal Medicine, Clinical Therapeutics, Current Medical Research and Opinion, Diabetes Care, Diabetes Obesity and Metabolism, Diabetic Medicine, Diabetologia, European Journal of Health Economics, Expert Opinions in Pharmacology, International Society for Pharmacoeconomics and Outcomes Research, Journal of the American Medical Association (JAMA), PharmacoEconomics, Swiss Medical Weekly and Value in Health. He has participated in numerous advisory boards and been a key member of several major medical and health economics workshops.

Total publications

155

Journal Article

(140 outputs)
YearCitationAltmetrics
2017Si L, Chen M, Palmer AJ, 'Has equity in government subsidy on healthcare improved in China? Evidence from the China's National Health Services Survey', International Journal for Equity in Health, 16, (1) Article 6. ISSN 1475-9276 (2017) [Refereed Article]

DOI: 10.1186/s12939-017-0516-z [eCite] [Details]

Co-authors: Si L

Tweet

2017Wang L, Palmer AJ, Cocker F, Sanderson K, 'Multimorbidity and health-related quality of life (HRQoL) in a nationally representative population sample: implications of count versus cluster method for defining multimorbidity on HRQoL', Health and Quality of Life Outcomes, 15, (1) Article 7. ISSN 1477-7525 (2017) [Refereed Article]

DOI: 10.1186/s12955-016-0580-x [eCite] [Details]

Co-authors: Wang L; Sanderson K

Tweet

2017de Graaff B, Si L, Neil AL, Yee KC, Sanderson K, et al., 'Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model', PharmacoEconomics - Open, 1, (1) pp. 37-51. ISSN 2509-4254 (2017) [Refereed Article]

DOI: 10.1007/s41669-016-0005-0 [eCite] [Details]

Co-authors: de Graaff B; Si L; Neil AL; Yee KC; Sanderson K

Tweet

2016de Graaff B, Neil A, Si L, Yee KC, Sanderson K, et al., 'Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia', Applied Health Economics and Health Policy pp. 1-14. ISSN 1175-5652 (2016) [Refereed Article]

DOI: 10.1007/s40258-016-0297-3 [eCite] [Details]

Co-authors: de Graaff B; Neil A; Si L; Yee KC; Sanderson K

Tweet

2016Annear MJ, Tierney LT, Vickers JC, Palmer AJ, 'Counting the cost of dementia-related hospital admissions: a regional investigation', Australasian Journal on Ageing, 35, (3) pp. E32-E35. ISSN 1440-6381 (2016) [Refereed Article]

DOI: 10.1111/ajag.12318 [eCite] [Details]

Co-authors: Annear MJ; Tierney LT; Vickers JC

Tweet

2016Chen M, Palmer AJ, Si L, 'Assessing equity in benefit distribution of government health subsidy in 2012 across East China: benefit incidence analysis', International Journal for Equity in Health, 15 Article 15. ISSN 1475-9276 (2016) [Refereed Article]

DOI: 10.1186/s12939-016-0306-z [eCite] [Details]

Co-authors: Si L

Tweet

2016Chen M, Si L, Winzenberg TM, Gu J, Jiang Q, et al., 'Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence', Patient Preference and Adherence, 10 pp. 415-423. ISSN 1177-889X (2016) [Refereed Article]

DOI: 10.2147/PPA.S100175 [eCite] [Details]

Co-authors: Si L; Winzenberg TM

Tweet

2016Hua X, Lung TWC, Palmer A, Si L, Herman WH, et al., 'How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes mellitus? a systematic review', PharmacoEconomics, (November) pp. 1-11. ISSN 1170-7690 (2016) [Refereed Article]

DOI: 10.1007/s40273-016-0466-0 [eCite] [Details]

Co-authors: Si L

Tweet

2016Kuzminov A, Palmer AJ, Wilkinson S, Khatsiev B, Venn AJ, 'Re-operations after Secondary Bariatric Surgery: a Systematic Review', Obesity Surgery, 26, (9) pp. 2237-2247. ISSN 0960-8923 (2016) [Refereed Article]

DOI: 10.1007/s11695-016-2252-7 [eCite] [Details]

Co-authors: Kuzminov A; Venn AJ

Tweet

2016Neil AL, Nelson M, Palmer AJ, 'The new Australian after-hours general practice incentive payment mechanism: equity for rural general practice?', Health Policy, 120, (7) pp. 809-817. ISSN 0168-8510 (2016) [Refereed Article]

DOI: 10.1016/j.healthpol.2016.05.005 [eCite] [Details]

Co-authors: Neil AL; Nelson M

Tweet

2016Petrie D, Lung TW, Rawshani A, Palmer AJ, Svensson AM, et al., 'Recent trends in life expectancy for people with type 1 diabetes in Sweden', Diabetologia, 59, (6) pp. 1167-1176. ISSN 0012-186X (2016) [Refereed Article]

DOI: 10.1007/s00125-016-3914-7 [eCite] [Details]

Citations: Scopus - 4Web of Science - 5

Tweet

2016Sharman MJ, Venn AJ, Hensher M, Wilkinson S, Palmer AJ, et al., 'Motivations for Seeking Bariatric Surgery: The Importance of Health Professionals and Social Networks', Bariatric Surgical Practice and Patient Care, 11, (3) pp. 104-109. ISSN 2168-023X (2016) [Refereed Article]

DOI: 10.1089/bari.2016.0004 [eCite] [Details]

Co-authors: Sharman MJ; Venn AJ; Williams D; Ezzy D

Tweet

2016Sharman MJ, Venn AJ, Jose KA, Williams Danielle, Hensher M, et al., 'The support needs of patients waiting for publicly funded bariatric surgery - implications for health service planners', Clinical Obesity, 7, (1) pp. 46-53. ISSN 1758-8103 (2016) [Refereed Article]

DOI: 10.1111/cob.12169 [eCite] [Details]

Co-authors: Sharman MJ; Venn AJ; Jose KA; Williams Danielle; Ezzy D

Tweet

2016Si L, Winzenberg TM, Chen M, Jiang Q, Neil A, et al., 'Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study', Osteoporosis International, 27, (7) pp. 2259-2269. ISSN 0937-941X (2016) [Refereed Article]

DOI: 10.1007/s00198-016-3502-1 [eCite] [Details]

Co-authors: Si L; Winzenberg TM; Neil A

Tweet

2016de Graaff B, Neil A, Sanderson K, Yee KC, Palmer AJ, 'Quality of life utility values for hereditary haemochromatosis in Australia', Health and Quality of Life Outcomes, 14, (1) Article 31. ISSN 1477-7525 (2016) [Refereed Article]

DOI: 10.1186/s12955-016-0431-9 [eCite] [Details]

Co-authors: de Graaff B; Neil A; Sanderson K; Yee KC

Tweet

2016de Graaff B, Neil A, Sanderson K, Yee KC, Palmer AJ, 'Costs associated with hereditary haemochromatosis in Australia: a cost-of-illness study', Australian Health Review pp. 1-14. ISSN 0156-5788 (2016) [Refereed Article]

DOI: 10.1071/AH15188 [eCite] [Details]

Co-authors: de Graaff B; Neil A; Sanderson K; Yee KC

Tweet

2016Campbell JA, Venn A, Neil A, Hensher M, Sharman M, et al., 'Diverse approaches to the health economic evaluation of bariatric surgery: a comprehensive systematic review', Obesity Reviews, 17, (9) pp. 850-894. ISSN 1467-7881 (2016) [Refereed Article]

DOI: 10.1111/obr.12424 [eCite] [Details]

Co-authors: Campbell JA; Venn A; Neil A; Sharman M

Tweet

2016Ahmad H, Taylor BV, van der Mei I, Colman S, O'Leary BA, et al., 'The impact of multiple sclerosis severity on health state utility values: Evidence from Australia', Multiple Sclerosis Journal, (September) pp. 1-10. ISSN 1352-4585 (2016) [Refereed Article]

DOI: 10.1177/1352458516672014 [eCite] [Details]

Co-authors: Ahmad H; Taylor BV; van der Mei I; Breslin M

Tweet

2016Campbell JA, Palmer AJ, Venn A, Sharman M, Otahal P, et al., 'A head-to-head comparison of the EQ-5D-5L and AQoL-8D multi-attribute utility instruments in patients who have previously undergone bariatric surgery', The Patient, 9, (4) pp. 311-322. ISSN 1178-1653 (2016) [Refereed Article]

DOI: 10.1007/s40271-015-0157-5 [eCite] [Details]

Citations: Web of Science - 1

Co-authors: Campbell JA; Venn A; Sharman M; Otahal P; Neil A

Tweet

2015Curry BA, Hitchens PL, Otahal P, Si L, Palmer AJ, 'Workplace injuries in thoroughbred racing: An analysis of insurance payments and injuries amongst jockeys in Australia from 2002 to 2010', Animals, 5, (3) pp. 897-909. ISSN 2076-2615 (2015) [Refereed Article]

DOI: 10.3390/ani5030390 [eCite] [Details]

Citations: Scopus - 3

Co-authors: Curry BA; Hitchens PL; Otahal P; Si L

Tweet

2015Neil AL, Nelson MR, Richardson T, Mann-Leonard M, Palmer AJ, 'General practice after-hours incentive funding: a rationale for change', Medical Journal of Australia, 203, (2) pp. 82-85. ISSN 0025-729X (2015) [Refereed Article]

DOI: 10.5694/mja14.01229 [eCite] [Details]

Citations: Scopus - 1Web of Science - 1

Co-authors: Neil AL; Nelson MR

Tweet

2015Palmer AJ, Si L, Gordon JM, Saul T, Otahal P, et al., 'Investigating the costs of major and minor cycling crashes in Tasmania, Australia', Australian and New Zealand Journal of Public Health, 39, (5) pp. 485-490. ISSN 1753-6405 (2015) [Refereed Article]

DOI: 10.1111/1753-6405.12384 [eCite] [Details]

Co-authors: Si L; Gordon JM; Saul T; Otahal P; Hitchens PL

Tweet

2015Sharman Melanie, Hensher M, Wilkinson S, Williams D, Palmer A, et al., 'What are the support experiences and needs of patients who have received bariatric surgery?', Health Expectations pp. 1-12. ISSN 1369-6513 (2015) [Refereed Article]

DOI: 10.1111/hex.12423 [eCite] [Details]

Co-authors: Sharman Melanie; Williams D; Venn A; Ezzy D

Tweet

2015Curry BA, Hitchens PL, Otahal P, Si L, Palmer AJ, 'Australian insurance costs of jockeys injured in a race-day fall', Occupational Medicine, 66, (3) pp. 222-229. ISSN 1471-8405 (2015) [Refereed Article]

DOI: 10.1093/occmed/kqv150 [eCite] [Details]

Citations: Scopus - 1

Co-authors: Curry BA; Hitchens PL; Otahal P; Si L

Tweet

2015Si L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ, 'Projection of osteoporosis-related fractures and costs in China: 2010-2050', Osteoporosis International, 26, (7) pp. 1929-1937. ISSN 0937-941X (2015) [Refereed Article]

DOI: 10.1007/s00198-015-3093-2 [eCite] [Details]

Citations: Scopus - 9Web of Science - 7

Co-authors: Si L; Winzenberg TM

Tweet

2015Si L, Winzenberg TM, Jiang Q, Palmer AJ, 'Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model', Osteoporosis International, 26, (5) pp. 1477-1489. ISSN 0937-941X (2015) [Refereed Article]

DOI: 10.1007/s00198-014-2999-4 [eCite] [Details]

Citations: Scopus - 4Web of Science - 6

Co-authors: Si L; Winzenberg TM

Tweet

2015de Graaff B, Neil A, Sanderson K, Si L, Yee KC, et al., 'A systematic review and narrative synthesis of health economic studies conducted for hereditary haemochromatosis', Applied Health Economics and Health Policy, 13, (5) pp. 469-483. ISSN 1175-5652 (2015) [Refereed Article]

DOI: 10.1007/s40258-015-0189-y [eCite] [Details]

Citations: Scopus - 2Web of Science - 1

Co-authors: de Graaff B; Neil A; Sanderson K; Si L; Yee KC

Tweet

2015Baxter S, Campbell S, Sanderson K, Cazaly C, Venn A, et al., 'Development of the Workplace Health Savings Calculator: a practical tool to measure economic impact from reduced absenteeism and staff turnover in workplace health promotion', BMC Research Notes, 8 Article 457. ISSN 1756-0500 (2015) [Refereed Article]

DOI: 10.1186/s13104-015-1402-7 [eCite] [Details]

Citations: Scopus - 1

Co-authors: Baxter S; Sanderson K; Venn A

Tweet

2015Si L, Winzenberg TM, Chen M, Jiang Q, Palmer AJ, 'Residual lifetime and 10 year absolute risks of osteoporotic fractures in Chinese men and women', Current Medical Research and Opinion, 31, (6) pp. 1149-1156. ISSN 0300-7995 (2015) [Refereed Article]

DOI: 10.1185/03007995.2015.1037729 [eCite] [Details]

Citations: Scopus - 4Web of Science - 4

Co-authors: Si L; Winzenberg TM

Tweet

2014Baxter S, Sanderson K, Venn AJ, Blizzard CL, Palmer AJ, 'The relationship between return on investment and quality of study methodology in workplace health promotion programs', American Journal of Health Promotion, 28, (6) pp. 347-363. ISSN 0890-1171 (2014) [Refereed Article]

DOI: 10.4278/ajhp.130731-LIT-395 [eCite] [Details]

Citations: Scopus - 37Web of Science - 32

Co-authors: Baxter S; Sanderson K; Venn AJ; Blizzard CL

Tweet

2014Cocker F, Nicholson JM, Graves N, Oldenburg B, Palmer AJ, et al., 'Depression in working adults: comparing the costs and health outcomes of working when ill', PLoS One, 9, (9) Article e105430. ISSN 1932-6203 (2014) [Refereed Article]

DOI: 10.1371/journal.pone.0105430 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Cocker F; Martin A; Scott J; Venn A; Sanderson K

Tweet

2014Baxter S, Sanderson K, Venn A, Otahal P, Palmer AJ, 'Construct validity of SF-6D health state utility values in an employed population', Quality of Life Research pp. 1-20. ISSN 1573-2649 (2014) [Refereed Article]

DOI: 10.1007/s11136-014-0823-4 [eCite] [Details]

Citations: Scopus - 1

Co-authors: Baxter S; Sanderson K; Venn A; Otahal P

Tweet

2014Elliott K-E, Annear MJ, Bell EJ, Palmer AJ, Robinson AL, 'Residents with mild cognitive decline and family members report health students 'enhance capacity of care' and bring 'a new breath of life' in two aged care facilities in Tasmania', Health Expectations pp. 1-14. ISSN 1369-6513 (2014) [Refereed Article]

DOI: 10.1111/hex.12236 [eCite] [Details]

Citations: Scopus - 2

Co-authors: Elliott K-E; Annear MJ; Bell EJ; Robinson AL

Tweet

2014Hitchens PL, Curry B, Blizzard CL, Palmer AJ, 'A decision tree model for the implementation of a safety strategy in the horse-racing industry', Injury Prevention pp. 1-7. ISSN 1475-5785 (2014) [Refereed Article]

DOI: 10.1136/injuryprev-2014-041223 [eCite] [Details]

Citations: Scopus - 1

Co-authors: Hitchens PL; Curry B; Blizzard CL

Tweet

2014Liebl A, Seitz L, Palmer AJ, 'Health economics analysis of insulin aspart vs. regular human insulin in Type 2 Diabetes patients, based on observational real life evidence from general practices in Germany', Experimental and Clinical Endocrinology & Diabetes, 122, (9) pp. 517-522. ISSN 0947-7349 (2014) [Refereed Article]

DOI: 10.1055/s-0034-1376987 [eCite] [Details]

Citations: Scopus - 1Web of Science - 1

Tweet

2014Lung TWC, Hayes AJ, Herman WH, Si L, Palmer AJ, et al., 'A meta-analysis of the relative risk of mortality for type 1 diabetes patients compared to the general population: exploring temporal changes in relative mortality', PL o S One, 9, (11) Article e113635. ISSN 1932-6203 (2014) [Refereed Article]

DOI: 10.1371/journal.pone.0113635 [eCite] [Details]

Citations: Scopus - 4Web of Science - 4

Co-authors: Si L

Tweet

2014Lung TWC, Petrie D, Herman WH, Palmer AJ, Svensson AM, et al., 'Severe hypoglycemia and mortality after cardiovascular events for Type 1 diabetic patients in Sweden', Diabetes Care, 37, (11) pp. 2974-2981. ISSN 0149-5992 (2014) [Refereed Article]

DOI: 10.2337/dc14-0405 [eCite] [Details]

Citations: Scopus - 15Web of Science - 13

Tweet

2014Palmer AJ, Si L, Gordon JM, Saul T, Curry BA, et al., 'Accident rates amongst regular bicycle riders in Tasmania, Australia', Accident Analysis and Prevention, 72 pp. 376-381. ISSN 0001-4575 (2014) [Refereed Article]

DOI: 10.1016/j.aap.2014.07.015 [eCite] [Details]

Citations: Scopus - 3

Co-authors: Si L; Gordon JM; Saul T; Curry BA; Otahal P; Hitchens PL

Tweet

2014Si L, Winzenberg TM, Palmer AJ, 'A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures', Osteoporosis International, 25, (1) pp. 51-60. ISSN 0937-941X (2014) [Refereed Article]

DOI: 10.1007/s00198-013-2551-y [eCite] [Details]

Citations: Scopus - 20Web of Science - 18

Co-authors: Si L; Winzenberg TM

Tweet

2014Si L, Winzenberg TM, de Graaff B, Palmer AJ, 'A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions', Osteoporosis International, 25, (8) pp. 1987-1997. ISSN 0937-941X (2014) [Refereed Article]

DOI: 10.1007/s00198-014-2636-2 [eCite] [Details]

Citations: Scopus - 13Web of Science - 11

Co-authors: Si L; Winzenberg TM; de Graaff B

Tweet

2014De Smit E, Palmer AJ, Hewitt AW, 'Projected worldwide disease burden from giant cell arteritis by 2050', Journal of Rheumatology, 42, (1) pp. 119-125. ISSN 1499-2752 (2014) [Refereed Article]

DOI: 10.3899/jrheum.140318 [eCite] [Details]

Citations: Scopus - 9Web of Science - 10

Co-authors: Hewitt AW

Tweet

2013McKercher CM, Venn AJ, Blizzard L, Nelson MR, Palmer AJ, et al., 'Psychosocial factors in adults with chronic kidney disease: characteristics of pilot participants in the Tasmanian Chronic Kidney Disease study', BMCNephrology, 14, (83) pp. 1-9. ISSN 1471-2369 (2013) [Refereed Article]

DOI: 10.1186/1471-2369-14-83 [eCite] [Details]

Citations: Scopus - 11Web of Science - 9

Co-authors: McKercher CM; Venn AJ; Blizzard L; Nelson MR; Ashby MA; Scott JL; Jose MD

Tweet

2013Palmer AJ, Colman S, O'Leary B, Taylor BV, Simmons RD, 'The economic impact of multiple sclerosis in Australia in 2010', Multiple Sclerosis, 19, (12) pp. 1640-1646. ISSN 1352-4585 (2013) [Refereed Article]

DOI: 10.1177/1352458513488230 [eCite] [Details]

Citations: Scopus - 14Web of Science - 9

Co-authors: Taylor BV

Tweet

2013Palmer AJ, Hitchens PL, Simpson Jr S, O'Leary B, Colman S, et al., 'A novel method for calculating prevalence of multiple sclerosis in Australia', Multiple Sclerosis, 19, (13) pp. 1704-1711. ISSN 1352-4585 (2013) [Refereed Article]

DOI: 10.1177/1352458513479841 [eCite] [Details]

Citations: Scopus - 6Web of Science - 5

Co-authors: Hitchens PL; Simpson Jr S; Taylor BV

Tweet

2013Taylor BV, Palmer A, Simpson Jr S, Lucas R, Simmons RD, et al., 'Assessing possible selection bias in a national voluntary MS longitudinal study in Australia', Multiple Sclerosis, 19, (12) pp. 1627-1631. ISSN 1352-4585 (2013) [Refereed Article]

DOI: 10.1177/1352458513481511 [eCite] [Details]

Citations: Scopus - 7Web of Science - 7

Co-authors: Taylor BV; Simpson Jr S

Tweet

2013Palmer AJ, 'Computer modeling of diabetes and its complications: a report on the fifth Mount Hood challenge meeting', Value in Health, 16, (4) pp. 670-685. ISSN 1098-3015 (2013) [Refereed Article]

DOI: 10.1016/j.jval.2013.01.002 [eCite] [Details]

Citations: Scopus - 43Web of Science - 36

Tweet

2012Hitchens PL, Palmer AJ, 'Characteristics of, and insurance payments for, injuries to cyclists in Tasmania, 1990-2010', Accident Analysis & Prevention, 49 pp. 449-456. ISSN 0001-4575 (2012) [Refereed Article]

DOI: 10.1016/j.aap.2012.03.013 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Hitchens PL

Tweet

2012Cooper MS, Palmer AJ, Seibel MJ, 'Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study', Osteoporosis International, 23, (1) pp. 97-107. ISSN 1433-2965 (2012) [Refereed Article]

DOI: 10.1007/s00198-011-1802-z [eCite] [Details]

Citations: Scopus - 36Web of Science - 35

Tweet

2012Palmer AJ, Tucker DMD, 'Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis', Primary Care Diabetes, 6, (2) pp. 109-121. ISSN 1751-9918 (2012) [Refereed Article]

DOI: 10.1016/j.pcd.2011.10.006 [eCite] [Details]

Citations: Scopus - 15Web of Science - 14

Co-authors: Tucker DMD

Tweet

2011Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M, 'Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents', Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy, 33, (11) pp. 1698-1712. ISSN 0149-2918 (2011) [Refereed Article]

DOI: 10.1016/j.clinthera.2011.09.022 [eCite] [Details]

Citations: Scopus - 13Web of Science - 11

Tweet

2009Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, et al., 'Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive', Value in Health, 12, (1) pp. 1-9. ISSN 1098-3015 (2009) [Refereed Article]

DOI: 10.1111/j.1524-4733.2008.00403.x [eCite] [Details]

Citations: Scopus - 7Web of Science - 7

Tweet

2008Gaede P, Valentine WJ, Palmer AJ, Tucker DMD, Lammert M, et al., 'Cost-effectiveness of Intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the Steno-2 study', Diabetes Care, 31, (8) pp. 1510-1515. ISSN 0149-5992 (2008) [Refereed Article]

DOI: 10.2337/dc07-2452 [eCite] [Details]

Citations: Scopus - 85Web of Science - 71

Tweet

2008Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, et al., 'Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting', International Journal of Clinical Practice, 62, (6) pp. 869-876. ISSN 1368-5031 (2008) [Refereed Article]

DOI: 10.1111/j.1742-1241.2008.01766.x [eCite] [Details]

Citations: Scopus - 10Web of Science - 6

Tweet

2008Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, et al., 'Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand', Value in Health, 11, (Supplement 1) pp. S43-S51. ISSN 1098-3015 (2008) [Refereed Article]

DOI: 10.1111/j.1524-4733.2008.00366.x [eCite] [Details]

Citations: Scopus - 12Web of Science - 9

Tweet

2008Palmer AJ, Lammert M, Hermansen K, 'Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark', Ugeskrift for Laeger , 170, (15) pp. 1250-1254. ISSN 1603-6824 (2008) [Refereed Article]

PMID: 18433583 [eCite] [Details]

Citations: Scopus - 5

Tweet

2008Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, et al., 'A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA', Nephrology, Dialysis and Transplantation, 23, (4) pp. 1216-1223. ISSN 0931-0509 (2008) [Refereed Article]

DOI: 10.1093/ndt/gfn082 [eCite] [Details]

Citations: Scopus - 46Web of Science - 39

Tweet

2008Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, et al., 'Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study', Current Medical Research and Opinion, 24, (5) pp. 1417-1428 . ISSN 0300-7995 (2008) [Refereed Article]

DOI: 10.1185/030079908X297295 [eCite] [Details]

Citations: Scopus - 12Web of Science - 6

Tweet

2008Ray JA, Borker R, Barber B, Valentine WJ, Belozeroff V, et al., 'Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA', Value in Health, 11, (5) pp. 800-808. ISSN 1098-3015 (2008) [Refereed Article]

DOI: 10.1111/j.1524-4733.2008.00329.x [eCite] [Details]

Citations: Scopus - 11Web of Science - 10

Tweet

2008Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, et al., 'Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes', Advances in Therapy: The International Journal of Drug, Device and Diagnostic Research, 25, (6) pp. 567-584. ISSN 0741-238X (2008) [Refereed Article]

DOI: 10.1007/s12325-008-0069-z [eCite] [Details]

Citations: Scopus - 20Web of Science - 10

Tweet

2008Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, et al., 'Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus', Value in Health, 11, (1) pp. 22-33. ISSN 1098-3015 (2008) [Refereed Article]

DOI: 10.1111/j.1524-4733.2007.00211.x [eCite] [Details]

Citations: Scopus - 28Web of Science - 23

Tweet

2007Alberti KGMM, Zimmet P, Shaw J, Unwin N, Orchard T, et al., 'International Diabetes Federation: a consensus on Type 2 diabetes prevention', Diabetic Medicine, 24, (5) pp. 451-463. ISSN 0742-3071 (2007) [Refereed Article]

DOI: 10.1111/j.1464-5491.2007.02157.x [eCite] [Details]

Citations: Scopus - 333Web of Science - 260

Tweet

2007Annemans L, Demarteau N, Hu SL, Lee TJ, Morad Z, et al., 'An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy', Value in Health, 11, (3) pp. 354-364. ISSN 1098-3015 (2007) [Refereed Article]

DOI: 10.1111/j.1524-4733.2007.00250.x [eCite] [Details]

Citations: Scopus - 11Web of Science - 8

Tweet

2007Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, et al., 'Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin: Economic Comparison in Adult and Adolescent Type 1 Diabetes Mellitus in Australia', Pharmacoeconomics, 25, (10) pp. 881-897. ISSN 1170-7690 (2007) [Refereed Article]

DOI: 10.2165/00019053-200725100-00006 [eCite] [Details]

Citations: Scopus - 32Web of Science - 19

Tweet

2007Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, et al., 'Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective', Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy, 29, (7) pp. 1508-1523. ISSN 0149-2918 (2007) [Refereed Article]

DOI: 10.1016/j.clinthera.2007.07.029 [eCite] [Details]

Citations: Scopus - 11Web of Science - 10

Tweet

2007Erny-Albrecht K, Valentine WJ, Christensen J, Vestenbaek U, Palmer AJ, 'Sublingual Immunotherapy in Allergic Rhinitis and Asthma: A Review of Recent Clinical Evidence', Journal of Applied Research: in Clinical and Experimental Therapeutics, 7, (1) pp. 17-31. ISSN 1537-064X (2007) [Refereed Article]

[eCite] [Details]

2007Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA, et al., 'Cost-effectiveness of diabetes case management for low-income populations', Health Services Research, 42, (5) pp. 1943-1959. ISSN 0017-9124 (2007) [Refereed Article]

DOI: 10.1111/j.1475-6773.2007.00701.x [eCite] [Details]

Citations: Scopus - 44Web of Science - 36

Tweet

2007Palmer AJ, Roze S, Valentine WJ, McEwan P, Gillett M, et al., 'Computer modeling of diabetes and its complications - A report on the Fourth Mount Hood Challenge Meeting', Diabetes Care, 30, (6) pp. 1638-1646. ISSN 0149-5992 (2007) [Refereed Article]

DOI: 10.2337/dc07-9919 [eCite] [Details]

Citations: Scopus - 136Web of Science - 90

Tweet

2007Palmer AJ, Valentine WJ, Ray JA, 'Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis', International Journal of Clinical Practice, 61, (10) pp. 1626-1633. ISSN 1368-5031 (2007) [Refereed Article]

DOI: 10.1111/j.1742-1241.2007.01343.x [eCite] [Details]

Citations: Scopus - 6Web of Science - 5

Tweet

2007Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, et al., 'An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK', Current Medical Research and Opinion, 23, (4) pp. 895-901. ISSN 0300-7995 (2007) [Refereed Article]

DOI: 10.1185/030079907X182194 [eCite] [Details]

Citations: Scopus - 23Web of Science - 16

Tweet

2007Palmer AJ, Valentine WJ, Ray JA, Roze S, Muszbek N, 'Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis', The European Journal of Health Economics, 8, (2) pp. 161-168. ISSN 1618-7598 (2007) [Refereed Article]

DOI: 10.1007/s10198-006-0033-2 [eCite] [Details]

Citations: Scopus - 7Web of Science - 6

Tweet

2007Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, et al., 'Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes', Current Medical Research and Opinion, 23, (3) pp. 609-622. ISSN 0300-7995 (2007) [Refereed Article]

DOI: 10.1185/030079907X178685 [eCite] [Details]

Citations: Scopus - 43Web of Science - 29

Tweet

2007Ray JA, Valentine WJ, Palmer AJ, 'Cost-utility analysis of cinacalcet in addition to standard of care in the UK', Nephrology, Dialysis and Transplantation, 22, (11) pp. 3355-3357. ISSN 0931-0509 (2007) [Refereed Article]

DOI: 10.1093/ndt/gfm434 [eCite] [Details]

Citations: Scopus - 4Web of Science - 4

Tweet

2007Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, et al., 'Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US', Diabetes Obesity & Metabolism, 9, (1) pp. 103-113. ISSN 1462-8902 (2007) [Refereed Article]

DOI: 10.1111/j.1463-1326.2006.00581.x [eCite] [Details]

Citations: Scopus - 25Web of Science - 17

Tweet

2007Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V, et al., 'PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK', Diabetic Medicine, 24, (9) pp. 982-1002. ISSN 0742-3071 (2007) [Refereed Article]

DOI: 10.1111/j.1464-5491.2007.02188.x [eCite] [Details]

Citations: Scopus - 24Web of Science - 17

Tweet

2007Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, et al., 'Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States', Advances in Therapy: The International Journal of Drug, Device and Diagnostic Research, 24, (2) pp. 273-290. ISSN 0741-238X (2007) [Refereed Article]

DOI: 10.1007/BF02849895 [eCite] [Details]

Citations: Scopus - 20Web of Science - 12

Tweet

2006Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S, 'Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets', International Journal of Clinical Practice, 60, (9) pp. 1138-1145. ISSN 1368-5031 (2006) [Refereed Article]

DOI: 10.1111/j.1742-1241.2006.01102.x [eCite] [Details]

Citations: Scopus - 24Web of Science - 20

Tweet

2006Bottomley J, Palmer AJ, Williams R, Dormandy J, Massi-Benedetti M, 'PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events - economic implications?', British Journal of Diabetes and Vascular Disease , 6, (2) pp. 63-70. ISSN 1474-6514 (2006) [Refereed Article]

DOI: 10.1177/14746514060060020401 [eCite] [Details]

Citations: Scopus - 7

Tweet

2006Palmer AJ, Currie CJ, 'Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes', Pharmacoeconomics, 24, (9) pp. 927-929. ISSN 1170-7690 (2006) [Contribution to Refereed Journal]

DOI: 10.2165/00019053-200624090-00009 [eCite] [Details]

Citations: Scopus - 2

Tweet

2006Palmer AJ, Dinneen S, Gavin JR, Gray A, Herman WH, et al., 'Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes', Current Medical Research and Opinion, 22, (5) pp. 861-872. ISSN 0300-7995 (2006) [Refereed Article]

DOI: 10.1185/030079906X104669 [eCite] [Details]

Citations: Scopus - 40Web of Science - 27

Tweet

2006Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, et al., 'Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy', Deutsche Medizinische Wochenschrift, 131, (31-32) pp. 1721-1726. ISSN 0012-0472 (2006) [Refereed Article]

DOI: 10.1055/s-2006-947822 [eCite] [Details]

Citations: Scopus - 6Web of Science - 6

Tweet

2006Palmer AJ, Roze S, Valentine WJ, Ray JA, Frei A, et al., 'Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland', Swiss Medical Weekly, 136, (21-22) pp. 346-352. ISSN 1424-7860 (2006) [Refereed Article]

PMID: 16779715 [eCite] [Details]

Citations: Scopus - 6Web of Science - 4

Tweet

2006Palmer AJ, Valentine WJ, Tucker DMD, Ray JA, Roze S, et al., 'A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension', Current Medical Research and Opinion, 22, (11) pp. 2095-2100. ISSN 0300-7995 (2006) [Refereed Article]

DOI: 10.1185/030079906X132730 [eCite] [Details]

Citations: Scopus - 8Web of Science - 7

Tweet

2006Roze S, Liens D, Palmer AJ, Berger W, Tucker D, et al., 'A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease', Current Medical Research and Opinion, 22, (12) pp. 2549-2556. ISSN 0300-7995 (2006) [Refereed Article]

DOI: 10.1185/030079906X148490 [eCite] [Details]

Citations: Scopus - 3Web of Science - 3

Tweet

2006Roze S, Valentine WJ, Evers T, Palmer AJ, 'Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting', Current Medical Research and Opinion, 22, (7) pp. 1415-1424. ISSN 0300-7995 (2006) [Refereed Article]

DOI: 10.1185/030079906X115531 [eCite] [Details]

Citations: Scopus - 7Web of Science - 5

Tweet

2006Roze S, Valentine WJ, Zakrzewska K, Palmer AJ, 'Cost-effectiveness of CSII - Response (Response to the letter by Philip Home)', Diabetic Medicine, 23, (6) pp. 707-708. ISSN 0742-3071 (2006) [Letter or Note in Journal]

DOI: 10.1111/j.1464-5491.2006.1854_2.x [eCite] [Details]

Tweet

2006Tucker DMD, Palmer AJ, Valentine WJ, Roze S, Ray JA, 'Counting the costs of overweight and obesity: modeling clinical and cost outcomes', Current Medical Research and Opinion, 22, (3) pp. 575-586. ISSN 0300-7995 (2006) [Refereed Article]

DOI: 10.1185/030079906X96227 [eCite] [Details]

Citations: Scopus - 23Web of Science - 19

Tweet

2006Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, et al., 'Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH', Advances in Therapy: The International Journal of Drug, Device and Diagnostic Research, 23, (2) pp. 191-207. ISSN 0741-238X (2006) [Refereed Article]

DOI: 10.1007/BF02850126 [eCite] [Details]

Citations: Scopus - 35Web of Science - 20

Tweet

2006Palmer AJ, Chen R, Valentine WJ, Roze S, Bregman B, et al., 'Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes', Diabetes & Metabolism, 32, (1) pp. 69-76. ISSN 1262-3636 (2006) [Refereed Article]

DOI: 10.1016/S1262-3636(07)70249-5 [eCite] [Details]

Citations: Scopus - 10Web of Science - 9

Tweet

2006Currie CJ, McEwan P, Poole C, Valentine WJ, Palmer AJ, et al., 'Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting', Current Medical Research and Opinion, 22, (5) pp. 967-969. ISSN 0300-7995 (2006) [Letter or Note in Journal]

DOI: 10.1185/030079906X00000 [eCite] [Details]

Tweet

2005Minshall ME, Roze S, Palmer AJ, Valentine WJ, Foos V, et al., 'Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States', Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy, 27, (6) pp. 940-950. ISSN 0149-2918 (2005) [Refereed Article]

DOI: 10.1016/j.clinthera.2005.06.006 [eCite] [Details]

Citations: Scopus - 27Web of Science - 21

Tweet

2005Palmer AJ, Annemans L, Roze S, Lapuerta P, Chen R, et al., 'Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria', Kidney International, 67, (Supplement 93) pp. S52-S54 . ISSN 0085-2538 (2005) [Refereed Article]

DOI: 10.1111/j.1523-1755.2005.09312.x [eCite] [Details]

Citations: Scopus - 15Web of Science - 9

Tweet

2005Palmer AJ, Tucker DMD, Ray JA, Valentine WJ, Currie C, et al., 'Insulin pumps: more consultation was needed', BMJ, 331, (7521) pp. 905-906. ISSN 0959-8146 (2005) [Letter or Note in Journal]

DOI: 10.1136/bmj.331.7521.905-c [eCite] [Details]

Tweet

2005Palmer AJ, Tucker DMD, Valentine WJ, Roze S, Gabriel S, et al., 'Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies', Nephrology, Dialysis and Transplantation, 20, (6) pp. 1103-1109. ISSN 0931-0509 (2005) [Refereed Article]

DOI: 10.1093/ndt/gfh802 [eCite] [Details]

Citations: Scopus - 19Web of Science - 12

Tweet

2005Palmer AJ, 'Health economics--what the nephrologist should know', Nephrology, Dialysis and Transplantation, 20, (6) pp. 1038-1041. ISSN 0931-0509 (2005) [Contribution to Refereed Journal]

[eCite] [Details]

2005Poldrugo F, Haeger DA, Comte S, Walburg J, Palmer AJ, 'A critical review of pharmacoeconomic studies of acamprosate', Alcohol and Alcoholism, 40, (5) pp. 422-430. ISSN 0735-0414 (2005) [Refereed Article]

DOI: 10.1093/alcalc/agh171 [eCite] [Details]

Citations: Scopus - 12Web of Science - 10

Tweet

2005Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, et al., 'Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain', Current Medical Research and Opinion, 21, (10) pp. 1617-1629. ISSN 0300-7995 (2005) [Refereed Article]

DOI: 10.1185/030079905X65349 [eCite] [Details]

Citations: Scopus - 66Web of Science - 52

Tweet

2005Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ, 'Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK', Diabetic Medicine, 22, (9) pp. 1239-1245. ISSN 0742-3071 (2005) [Refereed Article]

DOI: 10.1111/j.1464-5491.2005.01576.x [eCite] [Details]

Citations: Scopus - 65Web of Science - 55

Tweet

2005Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, et al., 'Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting', Current Medical Research and Opinion, 21, (12) pp. 2063-2071. ISSN 0300-7995 (2005) [Refereed Article]

DOI: 10.1185/030079905X74989 [eCite] [Details]

Citations: Scopus - 30Web of Science - 21

Tweet

2005Palmer AJ, Valentine WJ, Roze S, Lammert M, Spiesser J, et al., 'Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries', Current Medical Research and Opinion, 21, (1) pp. 19-26. ISSN 0300-7995 (2005) [Refereed Article]

DOI: 10.1185/030079904X17992 [eCite] [Details]

Citations: Scopus - 30Web of Science - 31

Tweet

2004Bergemann R, Brown J, Chan W, Clarke P, Eddy D, et al., 'Guidelines for computer modeling of diabetes and its complications', Diabetes Care, 27, (9) pp. 2262-2265. ISSN 0149-5992 (2004) [Refereed Article]

[eCite] [Details]

Citations: Web of Science - 88

2004Palmer AJ, Annemans L, Roze S, Lamotte A, Rodby RA, et al., 'Cost-effectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective', Nefrologia, 24, (3) pp. 231-238. ISSN 0211-6995 (2004) [Refereed Article]

[eCite] [Details]

Citations: Web of Science - 13

2004Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, et al., 'Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease', Diabetes Care, 27, (8) pp. 1897-1903. ISSN 0149-5992 (2004) [Refereed Article]

DOI: 10.2337/diacare.27.8.1897 [eCite] [Details]

Citations: Scopus - 66Web of Science - 56

Tweet

2004Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, et al., 'An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting', Journal of Human Hypertension, 18, (10) pp. 733-738. ISSN 0950-9240 (2004) [Refereed Article]

DOI: 10.1038/sj.jhh.1001729 [eCite] [Details]

Citations: Scopus - 28Web of Science - 19

Tweet

2004Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, et al., 'Health economic consequences of irbesartan treatment of type 2 diabetes patients with nephropathy and hypertension in German', Deutsche Medizinische Wochenschrift, 129, (1-2) pp. 13-18. ISSN 0012-0472 (2004) [Refereed Article]

DOI: 10.1055/s-2004-812656 [eCite] [Details]

Citations: Scopus - 18Web of Science - 14

Tweet

2004Palmer AJ, Rodby RA, 'Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria', Kidney International. Supplement , (92) pp. S118-S120. ISSN 0098-6577 (2004) [Refereed Article]

[eCite] [Details]

2004Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, et al., 'Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes', Current Medical Research and Opinion, 20, (Supplement 1) pp. S41-S51. ISSN 0300-7995 (2004) [Refereed Article]

DOI: 10.1185/030079904X2015 [eCite] [Details]

Citations: Scopus - 14Web of Science - 11

Tweet

2004Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, et al., 'The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making', Current Medical Research and Opinion, 20, (Supplement 1) pp. S5-S26. ISSN 0300-7995 (2004) [Refereed Article]

DOI: 10.1185/030079904X1980 [eCite] [Details]

Citations: Web of Science - 166

Tweet

2004Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, et al., 'Validation of the CORE Diabetes Model against epidemiological and clinical studies', Current Medical Research and Opinion, 20, (Supplement 1) pp. S27-S40. ISSN 0300-7995 (2004) [Refereed Article]

DOI: 10.1185/030079904X2006 [eCite] [Details]

Citations: Scopus - 173Web of Science - 114

Tweet

2004Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, et al., 'Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model', Current Medical Research and Opinion, 20, (1) pp. S53-S58. ISSN 0300-7995 (2004) [Refereed Article]

DOI: 10.1185/030079903125002611 [eCite] [Details]

Citations: Scopus - 26Web of Science - 16

Tweet

2004Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, et al., 'What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model', Current Medical Research and Opinion, 20, (1) pp. S59-S66. ISSN 0300-7995 (2004) [Refereed Article]

DOI: 10.1185/030079904X2024 [eCite] [Details]

Citations: Web of Science - 9

Tweet

2004Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, et al., 'Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy', Current Medical Research and Opinion, 20, (Supplement 1) pp. S67-S73. ISSN 0300-7995 (2004) [Refereed Article]

DOI: 10.1185/030079904X2033 [eCite] [Details]

Citations: Web of Science - 11

Tweet

2004Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU, 'Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials', Current Medical Research and Opinion, 20, (11) pp. 1729-1746 . ISSN 0300-7995 (2004) [Refereed Article]

DOI: 10.1185/030079904X5661 [eCite] [Details]

Citations: Scopus - 35Web of Science - 23

Tweet

2004Palmer AJ, Roze S, Valentine WJ, Spinas G, 'The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes: response to Scuffham [corrected] and Carr', Diabetic Medicine, 21, (12) pp. 1372-1372. ISSN 0742-3071 (2004) [Letter or Note in Journal]

DOI: 10.1111/j.1464-5491.2004.1349a.x [eCite] [Details]

Tweet

2004Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, et al., 'Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom', Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy, 26, (2) pp. 304-321. ISSN 0149-2918 (2004) [Refereed Article]

DOI: 10.1016/S0149-2918(04)90029-X [eCite] [Details]

Citations: Scopus - 86Web of Science - 62

Tweet

2003Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, et al., 'An Economic Evaluation of Irbesartan in the Treatment of Patients with Type 2 Diabetes, Hypertension and Nephropathy: Cost-Effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French Settings', Nephrology, Dialysis and Transplantation, 18, (10) pp. 2059-2066. ISSN 0931-0509 (2003) [Refereed Article]

DOI: 10.1093/ndt/gfg232 [eCite] [Details]

Citations: Scopus - 43Web of Science - 33

Tweet

2003Roze S, Palmer AJ, Valentine WJ, 'A multivariate logistic regression equation to screen for diabetes: response to Tabaei and Herman', Diabetes Care, 26, (5) pp. 1658-1659. ISSN 0149-5992 (2003) [Letter or Note in Journal]

DOI: 10.2337/diacare.26.5.1658 [eCite] [Details]

Citations: Scopus - 1

Tweet

2003Rodby RA, Chiou CF, Borenstein J, Smitten A, Sengupta N, et al., 'The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy', Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy, 25, (7) pp. 2102-2119 . ISSN 0149-2918 (2003) [Refereed Article]

DOI: 10.1016/S0149-2918(03)80208-4 [eCite] [Details]

Citations: Scopus - 42Web of Science - 24

Tweet

2002Coyle D, Palmer AJ, Tam R, 'Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada', Pharmacoeconomics, 20, (Supplement 1) pp. 31-42. ISSN 1170-7690 (2002) [Refereed Article]

DOI: 10.2165/00019053-200220001-00004 [eCite] [Details]

Citations: Web of Science - 18

Tweet

2002Sendi P, Palmer AJ, Hauri P, Craig BA, Horber FF, 'Modeling the impact of adjustable gastric banding on survival in patients with morbid obesity', Obesity Research, 10, (4) pp. 291-295. ISSN 1071-7323 (2002) [Refereed Article]

DOI: 10.1038/oby.2002.40 [eCite] [Details]

Citations: Web of Science - 4

Tweet

2001Gozzoli V, Palmer AJ, Brandt A, Spinas GA, 'Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting ', Swiss Medical Weekly, 131, (21-22) pp. 303-310. ISSN 1424-7860 (2001) [Refereed Article]

[eCite] [Details]

Citations: Web of Science - 16

2001Gozzoli V, Palmer AJ, Brandt A, Weiss C, Piehlmeier W, et al., 'Increased clinical and economic advantage of proteinuric screening and intervention (PROSIT project) in type 2 diabetics', Deutsche Medizinische Wochenschrift, 125, (39) pp. 1154-1159. ISSN 0012-0472 (2001) [Refereed Article]

DOI: 10.1055/s-2000-7670 [eCite] [Details]

Citations: Scopus - 19Web of Science - 12

Tweet

2001Palmer AJ, 'Commentary: Intensive glucose control is more costly than conventional treatment but also has more benefits for people with type-2 diabetes', Evidence - Based Healthcare and Public Health, 5, (1) pp. 17-18. ISSN 1744-2249 (2001) [Contribution to Refereed Journal]

DOI: 10.1054/ebhc.2000.0376 [eCite] [Details]

Tweet

2001Palmer AJ, Sendi PP, 'New aspects in health economic studies of prevention and treatment of osteoporosis', Expert Review of Pharmacoeconomics & Outcomes Research, 1, (2) pp. 198-204. ISSN 1744-8379 (2001) [Refereed Article]

DOI: 10.1586/14737167.1.2.198 [eCite] [Details]

Tweet

2001Sendi P, Palmer AJ, Gafni A, Battegay M, 'Highly Active Antiretroviral Therapy: Pharmacoeconomic issues in the management of HIV infection', Pharmacoeconomics, 19, (7) pp. 709-713. ISSN 1170-7690 (2001) [Refereed Article]

DOI: 10.2165/00019053-200119070-00001 [eCite] [Details]

Citations: Web of Science - 21

Tweet

2000Brown JB, Palmer AJ, Bisgaard P, Chan W, Pedula K, et al., 'The Mt. Hood Challenge: cross-testing two diabetes simulation models', Diabetes Research and Clinical Practice, 50, (Supplement 3) pp. S57-S64. ISSN 0168-8227 (2000) [Refereed Article]

DOI: 10.1016/S0168-8227(00)00217-5 [eCite] [Details]

Citations: Web of Science - 39

Tweet

2000Palmer AJ, Brandt A, Gozzoli V, Weiss C, Stock H, et al., 'Outline of a diabetes disease management model: principles and applications', Diabetes Research and Clinical Practice, 50, (Supplement 3) pp. S47-S56. ISSN 0168-8227 (2000) [Refereed Article]

DOI: 10.1016/S0168-8227(00)00216-3 [eCite] [Details]

Citations: Web of Science - 23

Tweet

2000Palmer AJ, Neeser K, Weiss C, Brandt A, Comte S, et al., 'The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate', Alcohol and Alcoholism, 35, (5) pp. 478-492. ISSN 0735-0414 (2000) [Refereed Article]

DOI: 10.1093/alcalc/35.5.478 [eCite] [Details]

Citations: Web of Science - 30

Tweet

2000Palmer AJ, Sendi PP, Spinas GA, 'Applying some UK Prospective Diabetes Study results to Switzerland: The cost-effectiveness of intensive glycemic control with metformin versus conventional control in overweight patients with type 2 diabetes', Schweizerische Medizinische Wochenschrift, 130, (27-28) pp. 1034-1040. ISSN 0036-7672 (2000) [Refereed Article]

[eCite] [Details]

Citations: Web of Science - 17

2000Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A, et al., 'The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective', Diabetologia: Clinical and Experimental Diabetes and Metabolism, 43, (1) pp. 13-26. ISSN 0012-186X (2000) [Refereed Article]

DOI: 10.1007/s001250050003 [eCite] [Details]

Citations: Web of Science - 63

Tweet

2000Sendi P, Palmer AJ, 'Modeling the socioeconomic impact of osteoporosis-related hip fractures in Switzerland', Osteoporosis International, 11, (1) pp. 92-94 . ISSN 0937-941X (2000) [Refereed Article]

DOI: 10.1007/s001980050011 [eCite] [Details]

Citations: Scopus - 6Web of Science - 5

Tweet

1999Palmer AJ, Sendi PP, 'Meta-analysis in oral health care', Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 87, (2) pp. 135-141. ISSN 1079-2104 (1999) [Refereed Article]

DOI: 10.1016/S1079-2104(99)70262-3 [eCite] [Details]

Citations: Web of Science - 6

Tweet

1999Sendi PP, Palmer AJ, Marinello CP, 'Some principles of cost-effectiveness analysis in dentistry', Acta Medicinae Dentium Helvetica, 4, (4) pp. 63-67. ISSN 1420-8873 (1999) [Refereed Article]

[eCite] [Details]

1998Neeser K, Brandt A, Palmer AJ, Volz A, 'Gesundheitsoekonomische Auswirkungen der Algodystrophie unter Einbezug von Calcitonin [Health economic effects of calcitonin on algodystrophy]', Managed Care (Switzerland), 1, (6) pp. 39-43. ISSN 1422-6618 (1998) [Refereed Article]

[eCite] [Details]

1998Palmer AJ, Neeser K, Paschen B, Cleland JGF, 'Economic implications of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up', Journal of Medical Economics , 1, (1-4) pp. 263-280. ISSN 1941-837X (1998) [Refereed Article]

DOI: 10.3111/199801263280 [eCite] [Details]

Citations: Scopus - 2

Tweet

1997Kirchhof B, Palmer AJ, Kakkar VV, Bergemann R, 'The Economic Burden of Deep Vein Thrombosis Sequelae: A Cost of Illness Analysis for Germany', Gesundheitsoekonomie und Qualitaetsmanagement , 2 pp. 40-44. ISSN 1439-4049 (1997) [Refereed Article]

[eCite] [Details]

1997Palmer AJ, Brandt A, 'The cost-effectiveness of gemcitabine plus cisplatin chemotherapy versus mitomycin ifosfamide and cisplatin (MIP), etopiside plus cisplatin, and vinorelbine plus cisplatin in the treatment of stages III B and IV non-small cell lung cancer: An Italian perspective (letter)', Monaldi Archives for Chest Disease, 52, (3) pp. 305-306. ISSN 1122-0643 (1997) [Letter or Note in Journal]

[eCite] [Details]

1997Palmer AJ, Koppenhagen K, Kirchhof B, Weber U, Bergemann R, 'Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thromboembolism prophylaxis in orthopaedic surgery: A meta-analysis of randomised clinical trials', Haemostasis, 27, (2) pp. 75-84. ISSN 0301-0147 (1997) [Refereed Article]

[eCite] [Details]

Citations: Web of Science - 64

1997Palmer AJ, Schramm W, Kirchhof B, Bergemann R, 'Low Molecular Weight Heparin for Prevention of Thromboembolism in General Surgery: A Meta-Analysis of Randomized Clinical Trials with Low Molecular Weight Heparin, Unfractionated Heparin, and Warfarin', Haemostasis, 27, (2) pp. 65-74. ISSN 0301-0147 (1997) [Refereed Article]

[eCite] [Details]

Citations: Web of Science - 51

1997Sendi PP, Palmer AJ, Marinello CP, 'Health State Utilities in Dentistry: A Review', Acta Medicinae Dentium Helvetica, 2, (10) pp. 243-248. ISSN 1420-8873 (1997) [Refereed Article]

[eCite] [Details]

1996Palmer AJ, Brandt A, 'The cost-effectiveness of gemcitabine plus cisplatin chemotherapy versus mitomycin ifosfamide and cisplatin (MIP), etopiside plus cisplatin, and vinorelbine plus cisplatin in the treatment of stages III B and IV non-small cell lung cancer: An Italian perspective', Monaldi Archives for Chest Disease, 51, (4) pp. 279-288. ISSN 1122-0643 (1996) [Refereed Article]

[eCite] [Details]

Chapter in Book

(1 outputs)
YearCitationAltmetrics
2014Si L, Palmer AJ, 'Prevention of T2DM: health economics', Diapedia. The living textbook of diabetes., R. Landgraf (ed) (2014) [Other Book Chapter]

DOI: 10.14496/dia.0104770156.4 [eCite] [Details]

Co-authors: Si L

Tweet

Review

(2 outputs)
YearCitationAltmetrics
2012Liebl A, Prusty V, Valensi P, Kawamori R, Christiansen JS, et al., 'Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings', Drugs, 72, (11) pp. 1495-1520. ISSN 0012-6667 (2012) [Substantial Review]

DOI: 10.2165/11635490-000000000-00000 [eCite] [Details]

Citations: Scopus - 21

Tweet

2011Tucker DMD, Palmer AJ, 'The cost-effectiveness of interventions in diabetes: A review of published economic evaluations in the UK setting, with an eye on the future', Primary Care Diabetes, 5, (1) pp. 9-17. (2011) [Substantial Review]

DOI: 10.1016/j.pcd.2010.10.001 [eCite] [Details]

Citations: Scopus - 4

Co-authors: Tucker DMD

Tweet

Conference Publication

(8 outputs)
YearCitationAltmetrics
2016Ahmad H, van der Mei I, Taylor B, Palmer AJ, 'PND13 - Assessing Health-State Utility Values in Australian People with Multiple Sclerosis', Value in Health, pp. A875, 19 (7). (2016) [Conference Extract]

DOI: 10.1016/j.jval.2016.08.342 [eCite] [Details]

Co-authors: Ahmad H; van der Mei I; Taylor B

Tweet

2016Palmer AJ, Taylor B, Van der Mei I, Si L, Ahmad H, 'CU3 - Life Expectancy, Quality-Adjusted Life Years, and Total Lifetime Costs for Australian People with Multiple Sclerosis', Value in Health, pp. A808, 19 (7). (2016) [Conference Extract]

DOI: 10.1016/j.jval.2016.08.722 [eCite] [Details]

Co-authors: Taylor B; Van der Mei I; Si L; Ahmad H

Tweet

2016Walters H, Tierney L, Annear M, Elliott KJ, Palmer A, et al., 'Assessment and management of chronic respiratory conditions in frail older adults', Respirology, pp. 145, 21 (2). ISSN 1323-7799 (2016) [Conference Extract]

DOI: 10.1111/resp.12755 [eCite] [Details]

Co-authors: Walters H; Tierney L; Annear M; Elliott KJ; Robinson A

Tweet

2016de Graaff BL, Neil A, Sanderson K, Yee KC, Palmer AJ, 'PND9 - An Australian National Cost of Illness Study For Hereditary Haemochromatosis', Value in Health, pp. A874, 19 (7). ISSN 1098-3015 (2016) [Conference Extract]

DOI: 10.1016/j.jval.2016.08.344 [eCite] [Details]

Co-authors: de Graaff BL; Neil A; Sanderson K; Yee KC

Tweet

2016de Graaff BL, Si L, Neil A, Yee KC, Sanderson K, et al., 'PND10 - Cost-Effectiveness of Population Screening for Haemochromatosis In Australia: A State-Transition Model', Value in Health, pp. A874-A875, Vol 19 (7). ISSN 1098-3015 (2016) [Conference Extract]

DOI: 10.1016/j.jval.2016.08.345 [eCite] [Details]

Co-authors: de Graaff BL; Si L; Neil A; Yee KC; Sanderson K

Tweet

2015de Graaff BL, Neil A, Sanderson K, Yee KC, Palmer A, 'The impact of increasing severity of hereditary haemochromatosis on health state utility values', Value in Health, pp. A300, Vol 18, A1-A307. ISSN 1098-3015 (2015) [Conference Extract]

[eCite] [Details]

Co-authors: de Graaff BL; Neil A; Sanderson K; Yee KC

2014McKercher C, Venn A, Blizzard CL, Nelson M, Palmer AJ, et al., 'Psychosocial factors in chronic kidney disease: 2 year follow-up of pilot participants', Nephrology, pp. 17-57, 19 (Supp 4). ISSN 1320-5358 (2014) [Conference Extract]

[eCite] [Details]

Co-authors: McKercher C; Venn A; Blizzard CL; Nelson M; Ashby M; Scott J; Jose MD

2013Elliott K-E, Annear MJ, Bell EJ, Palmer AJ, Robinson AL, 'Dementia tsunami in aged care: can students improve residents' quality of life?', The 46th Australian Association of Gerontology National Conference, 27-29 Nov, Sydeny, NSW (2013) [Conference Extract]

[eCite] [Details]

Co-authors: Elliott K-E; Annear MJ; Bell EJ; Robinson AL

Contract Report, Consultant's Report

(2 outputs)
YearCitationAltmetrics
2014Neil A, Nelson M, Palmer AJ, 'General Practice After Hours Practice Funding: 2014-15 Funding Model', Tasmania Medicare Local (2014) [Contract Report]

[eCite] [Details]

Co-authors: Neil A; Nelson M

2011Palmer AJ, 'Economic Impact of Multiple Sclerosis in 2010: Australian MS Longitudinal Study', Multiple Sclerosis Research Australia (2011) [Consultants Report]

[eCite] [Details]

Other Public Output

(2 outputs)
YearCitationAltmetrics
2016Neil A, de Graaff B, Chappell K, Sanderson K, Palmer A, et al., 'What Value GP Assist? The comparative benefits of, and satisfaction with GP Assist in Residential Aged Care Facilities and General Practice in Rural and Urban Tasmania', Department of Health and Human Services, Tasmanian Government (2016) [Government or Industry Research]

[eCite] [Details]

Co-authors: Neil A; de Graaff B; Chappell K; Sanderson K; Nelson M

2015Neil A, Nelson M, Sanderson K, Palmer A, 'Improving the availability and efficiency of appropriate urgent service provision in Tasmania: Interim evaluation of the GP Assist and the Tasmanian General Practice After-Hours Incentive Funding Model 2014-15', Tasmania Medicare Local (2015) [Government or Industry Research]

[eCite] [Details]

Co-authors: Neil A; Nelson M; Sanderson K

Grants & Funding

Funding Summary

Number of grants

19

Total funding

$7,659,638

Projects

AusGo-SHEMO..Let's Go! Australian Gold Standard Health Economics Model of Osteoporosis (2017 - 2019)$378,957
Description
We will develop an unbiased, gold standard, validated, transparent health economics model of osteoporosis to identify cost-effective screeningand treatment strategies, and that will be made widely available to all stakeholders. Without this model, scarce health care resources may besquandered on osteoporosis screening strategies and osteoporosis-related fracture prevention medications that are not cost-effective. Worse,patient access to cost-effective medications may be delayed.
Funding
National Health & Medical Research Council ($378,957)
Scheme
Grant-Project
Administered By
University of Tasmania
Research Team
Palmer AJ; Eisman JA; Si L; Winzenberg TM; Sanders K; Center J
Period
2017 - 2019
Grant Reference
1127827
Centre of Research Excellence in Pulmonary Fibrosis (2017 - 2021)$2,503,607
Description
The Centre for Research excellence in Pulmonary Fibrosis (CRE-PF) aims to develop a sustainable nation-wide network, consisting of world recognized experts. The group will enable an integrative approach to solving PF through a layered strategy extending from molecules germane to disease pathogenesis, to human studies. With this approach the CRE-PF will set a new paradigm for synergy between academia, health care, health policy and the public, placing Australia at the forefront of innovation.
Funding
National Health & Medical Research Council ($2,503,607)
Scheme
Grant-Centre of Research Excellence
Administered By
University of Sydney
Research Team
Palmer AJ; Walters EH; Corte T; Moodley Y; Glaspole I
Period
2017 - 2021
Grant Reference
APP1116371
Comparison of learning focused cardiac ultrasound between self-directed/simulator and instructor/live model teaching (2016)$32,000
Description
Our proposed project aims to test whether our new self-directed learning simulator course is as effective as the current standard teaching model that uses lots of instructors and human volunteer models. The advantages of the simulator course include reduced reliance on instructors, increased availability of the course (ability to train a lot more doctors than the current standard course) to and the ability to also teach learning of diagnosis of heart disease (not possible with the current human model). A health economic analysis will also be performed to determine if the new simulator course is as cost-effective (economical) as versus the traditional course. If the new course is as effective and economical as the current course then the simulator course may become the new method for teaching bedside ultrasound as it has important advantages over the traditional method such as increased accessibility and capacity to train doctors, and the ability to teach how to diagnose heart conditions. This would result in significant health benefits to a very large number of patients worldwide.
Funding
Australian and New Zealand College of Anaesthetists ($32,000)
Scheme
Grant - Project Grant Funding
Administered By
University of Tasmania
Research Team
Canty DJ; Royse A; Royse C; Palmer AJ
Year
2016
Does treating multiple sclerosis alter long-term disease outcomes? a natural history study (2016 - 2017)$180,000
Description
A natural history study of MS outcomes between a treated (Australian) versus untreated NZ population to study the long-term effects of MS disease modifying drugs. This is a clinical epidemiological project.
Funding
Multiple Sclerosis Research Australia ($180,000)
Scheme
Grant-Project
Administered By
University of Tasmania
Research Team
Taylor BVM; van der Mei IAF; Palmer AJ; Blizzard CL; Butzkueven H; Simpson Jr S; Kalincik T; Carroll W; Mason D
Period
2016 - 2017
Evaluation of new Tasmanian general practice after hours incentive funding model and the value for money of GP Assist (2015 - 2016)$159,970
Description
This project will encompass an evaluation of the after-hours incentive funding model and the value-for-money of the GP Assist after-hours telephone support service. This research project will: a) conduct and survey of Residential Aged Care Facilities pre- and post- implementation of the new funding model and a survey of general practices post-implementation of the funding model; b) provide an analysis of existing data collections on clinic hours and MBF billings data; c) deliver a final report based on the evaluation of the collected data, providing recommendations on the feasibility and ongoing sustainability of the model.
Funding
Primary Health Tasmania ($159,970)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Neil A; Nelson MR; Palmer AJ; Sanderson Kristy
Period
2015 - 2016
GP Assist Evaluation (2015)$31,335
Description
The University has been engaged by a third party Primary Health Tasmania to undertake collaborative research in relation to its funding of the GP Assist program and establishing whether it is adding value to the after-hours provision of general practice services to residential aged care facilities, palliative care services and the Tasmanian community (Third Party Services). The Crown is engaging the University under this Agreement to conduct additional research as part of the University undertaking the Third Party Services to determine whether the Crowns funding of GP Assist to further assess the GP Assists contribution (if any) to the efficiency and sustainability of the rural health services.
Funding
Department of Health and Human Services Tasmania ($31,335)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Neil A; Nelson MR; Palmer AJ; Sanderson Kristy
Year
2015
DEVA MS: DEvelopment and VAlidation of a cost effectiveness simulation model for Multiple Sclerosis and implications for health policy (2015 - 2016)$160,000
Description
The number of people with multiple sclerosis (MS) is increasing dramatically in Australia, with rapidly escalating associated costs, both direct due to medical expenses and indirect due to lost or reduced employment. Existing and upcoming treatments for MS are expensive, with current prices of up to $25,000 per patient per year and rising. Using the best available data, this study will identify the treatments that are greatest value for money for the most common form of MS (relapsing-remitting MS), with a goal to reduce wastage of limited healthcare resources.
Funding
Multiple Sclerosis Research Australia ($160,000)
Scheme
Grant-Project
Administered By
University of Tasmania
Research Team
Palmer AJ; Taylor BVM; van der Mei IAF; Clarke Philip; Simpson Jr S
Period
2015 - 2016
Provision of Health Economics consultancy service to develop a new Tasmanian GP After Hours Incentive Funding Model(s) (2014)$79,822
Description
This project will develop a series of increasingly redistributive funding models supporting the provision of accessible and effective after hours care throughout Tasmanian that address core objectives and identified areas of concern.
Funding
Primary Health Tasmania ($79,822)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Neil A; Palmer AJ; Nelson MR
Year
2014
Dementia-related presentations at the Royal Hobart Hospital - A pilot program for redesigning state-wide clinical care pathways involving Tasmanian residential aged care facilities (RACFs) and their c (2014)$6,873
Description
This project explores dementia-related presentations to the RHH to inform the development of new clinical pathways to reduce preventable and unplanned hospital transfers that are costly and have poor outcomes for people with dementia. Care pathways from RACFs and community settings to the RHH will be reviewed.
Funding
Royal Hobart Hospital Research Foundation ($6,873)
Scheme
Grant-Starter
Administered By
University of Tasmania
Research Team
Annear MJ; Nicols H; Powell D; Bell EJ; Elliott KJ; Palmer AJ; Vickers JC; Eccleston CEA; McInerney F
Year
2014
Clinical Redesign of respiratory pathways in residential aged care (2014)$80,000
Description
Respiratory conditions are a leading cause of unplanned admissions from residential aged care and the wider community. This project aims to reduce the burden of preventable unplanned admissions from aged care facilities and improve health outcomes.
Funding
University of Tasmania ($80,000)
Scheme
vTAHSP Demonstration Projects
Administered By
University of Tasmania
Research Team
Bell EJ; Robinson AL; Walters EH; Palmer AJ; Winter RE; Annear MJ; Elliott KJ
Year
2014
Improving prevention and early intervention for type 2 diabetes in Tasmania (2014)$54,673
Description
This project will use the AUSDRISK tool in a random mail-out to seniors card holders and via clinical contact at Clarence ICC (to increase the numbers of adults assessed in healthcare settings). Training will be provided for optomeyes and Clarence ICC personnel in the use of the tool. Follow up will be conducted with respondents who scored as being high risk, including recommended management by both the individual and their GP.
Funding
University of Tasmania ($54,673)
Scheme
vTAHSP Demonstration Projects
Administered By
University of Tasmania
Research Team
Macintyre K; Burgess JR; Palmer AJ; Shaw K; Bingham L
Year
2014
Bariatric surgery in Tasmania: investigating health service use, costs, patient outcomes and policy options (2014 - 2019)$839,027
Description
About 1 in 20 Tasmanians are severely obese. Bariatric surgery can improve health for individuals with severe obesity but access to surgery is poor for most public patients. This study will investigate the pathways of patients referred for bariatric surgery in the Tasmanian public and private hospital systems to better understand the demand for surgery, the health outcomes, and costs associated with these different pathways. The findings will inform public policy and resource allocation.
Funding
National Health & Medical Research Council ($644,027)
Collaborators
Department of Health and Human Services Tasmania ($150,000); Department of Premier and Cabinet ($45,000)
Scheme
Grant-Partnership Project
Administered By
University of Tasmania
Research Team
Venn A; Palmer AJ; Ezzy D; Blizzard CL; Nelson MR; Neil A
Period
2014 - 2019
Grant Reference
1076899
Bariatric surgery in Tasmanian public hospitals: investigating health service use, costs, and policy options (2014)$8,088
Description
Bariatric surgery is considered an effective treatment for significant obesity-related illness but it is difficult to access in Australian public hospitals. By describing Tasmanian public patients' characteristics, clinical pathways, costs and outcomes this project will support better informed decision-making about Tasmanian public hospital services for clinically obese patients.
Funding
Royal Hobart Hospital Research Foundation ($8,088)
Scheme
Grant-Starter
Administered By
University of Tasmania
Research Team
Venn A; Wilkinson Stephen; Greenaway T; Hensher M; Palmer AJ; Blizzard CL; Neil A
Year
2014
Guidance of Heart Failure Management Programs by Risk Assessment (2013 - 2018)$1,422,739
Description
The aims of this project are to reduce Heart Failure (HF) admissions and costs in Tasmania by: i) using data linkage to identify locations where community service delivery should be targeted, and to evaluate current performance in HF readmission across the State; ii) developing a risk algorithm for HF readmission, including psychosocial determinants; iii) using i) and ii) devising a novel means of providing a disease management program (DMP), titrated to risk assessment, with physiologic assessment used to guide the management of the highest risk patients; iv) developing a clinical trial to define the merits of this approach; v) evaluating the cost-effectiveness of this intervention; vi) presentation of educational activities with community-based providers. A successful intervention is likely to be sustainable. As HF readmissions in Tasmania cost ~4550 bed days/y, the investment in this grant (~$1/2m/y) could be reproduced by a 50% reduction of readmissions.
Funding
National Health & Medical Research Council ($942,739)
Scheme
Grant-Partnership Project
Administered By
University of Tasmania
Research Team
Marwick TH; Venn A; Sanderson Kristy; Nelson MR; Palmer AJ; Blizzard CL
Period
2013 - 2018
Grant Reference
1059738
Improving care through imbedding general practitioners within residential aged care facilities (2013 - 2015)$404,875
Funding
Bupa Foundation (Australia) Limited ($404,875)
Scheme
Grant-Expression of Interest Grants Program
Administered By
University of Tasmania
Research Team
Robinson AL; Haines Terry; Palmer AJ; Vickers JC
Period
2013 - 2015
Development and validation of a health policy simulation model for type 1 diabetes (2012 - 2014)$336,549
Funding
National Health & Medical Research Council ($336,549)
Scheme
Grant-Project
Administered By
University of Melbourne
Research Team
Palmer AJ; Clarke Philip; Milne George; Briggs Andrew; Herman W; Eliasson B
Period
2012 - 2014
Grant Reference
1028335
Epidemiology and economic impact of injuries to jockeys in the thoroughbred racing industry (2011 - 2012)$50,855
Funding
WorkCover Tasmania ($50,855)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Palmer AJ; Hitchens PL
Period
2011 - 2012
5th Mount Hood Challenge Conference Malmo Sweden 18-19 Sept 2011 (2010)$14,018
Funding
Janssen-Cilag Pty Ltd ($14,018)
Scheme
Consultancy
Administered By
University of Tasmania
Research Team
Palmer AJ
Year
2010
Improving health and wellbeing in the Tasmanian State Service workforce (2010 - 2014)$916,250
Funding
National Health & Medical Research Council ($856,250)
Scheme
Grant-Partnership Project
Administered By
University of Tasmania
Research Team
Venn A; Sanderson Kristy; Blizzard CL; Taylor Roscoe; Wood-Baker R; Palmer AJ; Nelson MR; Turner P
Period
2010 - 2014
Grant Reference
544954

Research Supervision

Current

5

Completed

3

Current

DegreeTitleCommenced
PhDBariatric surgery: Pathways, perspectives and policy options2013
PhDReducing the social, personal and public burden of obesity: an economic and epidemiological analysis2013
PhDMultimorbidity in the Australian working population: improving understanding of definitions and outcomes to improve management2013
PhDRevisional Bariatric Surgery: Predictors, Outcomes and Economic Impact on Tasmanian Healthcare2014
PhDImpact of Immunisation on Child Survival in Ghana: 1993-20142017

Completed

DegreeTitleCompleted
PhDThe Health Economics of Haemochromatosis
Candidate: Barbara de Graaff
2016
PhDHealth Economics in Osteoporosis: Construction and application of a new state-transition microsimulation model
Candidate: Lei Si
2016
PhDHealthy, wealthy and wise. Investigating the application of health economics in workplace health promotion: the economic evaluation of Healthy@Work
Candidate: Siyan Baxter
2015